GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » First Wave BioPharma Inc (NAS:FWBI) » Definitions » EPS without NRI
中文

First Wave BioPharma (First Wave BioPharma) EPS without NRI

: $-304.48 (TTM As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

First Wave BioPharma's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-2.68. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-304.48.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for First Wave BioPharma's EPS without NRI or its related term are showing as below:

FWBI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -175.6   Med: 9.05   Max: 74.9
Current: 74.9

FWBI's 3-Year EPS without NRI Growth Rate is ranked better than
96.91% of 1293 companies
in the Biotechnology industry
Industry Median: 4.6 vs FWBI: 74.90

First Wave BioPharma's EPS (Diluted) for the three months ended in Dec. 2023 was $-2.68. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-304.48.

First Wave BioPharma's EPS (Basic) for the three months ended in Dec. 2023 was $-2.68. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-304.48.


First Wave BioPharma EPS without NRI Historical Data

The historical data trend for First Wave BioPharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

First Wave BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,428.00 -3,037.75 -38,663.78 -369.29 -47.88

First Wave BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.08 -254.80 -37.80 -9.20 -2.68

Competitive Comparison

For the Biotechnology subindustry, First Wave BioPharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


First Wave BioPharma PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, First Wave BioPharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where First Wave BioPharma's PE Ratio without NRI falls into.



First Wave BioPharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-304.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


First Wave BioPharma  (NAS:FWBI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


First Wave BioPharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of First Wave BioPharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


First Wave BioPharma (First Wave BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Executives
James Sapirstein director, officer: President and CEO 1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano officer: Chief Financial Officer 271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman director 777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell director C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm director 1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes director 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington officer: CHIEF MEDICAL OFFICER 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman officer: CHIEF FINANCIAL OFFICER 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr. 10 percent owner C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor director, officer: President and CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda director 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc 10 percent owner PO BOX 2422, WESTPORT CT 06880

First Wave BioPharma (First Wave BioPharma) Headlines

From GuruFocus

First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

By Stock market mentor Stock market mentor 01-25-2023

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

By sperokesalga sperokesalga 02-13-2023

First Wave BioPharma to Present at the BIO CEO & Investor Conference

By Stock market mentor Stock market mentor 01-30-2023

First Wave BioPharma to Present at Sequire Biotechnology Conference

By Stock market mentor Stock market mentor 01-24-2023

First Wave BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

By Stock market mentor Stock market mentor 02-07-2023